Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785508 | 0.81 | CTRB1 (0.34) | — | |
| SCHEMBL7358051 | 0.81 | — | — | |
| SCHEMBL302005 | 0.68 | — | — | |
| Cyclohexanone SCHEMBL28357381 | 0.68 | TRIM24 (0.34) | — | |
| SCHEMBL26129174 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL8122291 | 0.67 | — | — | |
| SCHEMBL27526976 | 0.67 | MAPT (0.30) | — | |
| SCHEMBL27675698 | 0.67 | — | — | |
| SCHEMBL9344374 | 0.66 | — | — | |
| SCHEMBL2310348 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110917232-A | Method for applying medical natural product targeted medicine of dandelion extracted by hydrothermal method to mainly treat dermatitis allergy | 苏州科技大学 | 2020-03-27 | — | — | CN | claimed |
| CN-214937133-U | Delta-valerolactone purification device | 迈奇化学股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-109651318-B | Preparation method of valerolactone | 万华化学集团股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| CN-107987044-B | Method for preparing valerolactone | 万华化学集团股份有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-106674173-B | Dehydrogenation catalyst and method for preparing valerolactone | 万华化学集团股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| CN-110917232-A | Method for applying medical natural product targeted medicine of dandelion extracted by hydrothermal method to mainly treat dermatitis allergy | 苏州科技大学 | 2020-03-27 | — | — | CN | disclosed |
| CN-110917232-A | Method for applying medical natural product targeted medicine of dandelion extracted by hydrothermal method to mainly treat dermatitis allergy | 苏州科技大学 | 2020-03-27 | — | — | CN | disclosed |
| CN-107954951-B | Method for manufacturing delta-valerolactone | 万华化学集团股份有限公司 | 2020-03-03 | — | — | CN | disclosed |
| US-10336737-B2 | Metal catalyzed dearomative 1,2-carboamination | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180362513-A1 | METAL CATALYZED DEAROMATIVE 1,2-CARBOAMINATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3218425-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077513-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2011075353-A1 | COMPOSITION COMPRISING MICROCAPSULES | THE PROCTER & GAMBLE COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2003074044-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-09-12 | — | — | WO | disclosed |
| US-5750139-A | CONTAINED IN INNER SPACE BETWEEN IMPERMEABLE TOP LAYER AND MICROPOROUS MEMBRANE WELDED TOGATHER | DROSSAPHARM AG (CH) | 1998-05-12 | — | — | US | disclosed |
| EP-0668074-A1 | Pharmaceutical composition | Drossapharm AG (CH) | 1995-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336737-B2 | Metal catalyzed dearomative 1,2-carboamination | DNTT, DIMT1, NMT1 | TSHR 2648/4885 |
| US-20180362513-A1 | METAL CATALYZED DEAROMATIVE 1,2-CARBOAMINATION | DNTT, DIMT1, NMT1 | TSHR 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.